Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers

Yale University

Status

Completed

Conditions

Overweight

Obesity

Smoking Cessation

Treatments

Drug: Nicotine patch

Study type

Interventional

Funder types

Other

Identifiers

NCT01259466

1001006181

Details and patient eligibility

About

This project will be a randomized clinical trial testing the efficacy of an internet-administered smoking cessation treatment for overweight and obese smokers. Research on internet-administered behavioral treatments for smoking cessation has found that compared to control treatments (e.g., self-help materials), cessation rates in internet-administered treatments are significantly higher. Research testing the applicability of these treatments to overweight and obese individuals has not yet been conducted. Given that a substantial portion of smokers are also overweight and at elevated cardiovascular risk, there is a need for directed treatment efforts for this group. The current trial proposes to be the first to test the effectiveness of internet-administered smoking cessation treatment for overweight and obese (BMI≥25) smokers. Adult participants will be randomized to receive 12 weeks of internet-administered treatment consisting of either: a) standard smoking cessation treatment with general health education, or b) standard smoking cessation treatment with cognitive behavioral therapy (CBT) for weight concerns. Participants in both conditions will receive open-label treatment with the 21 mg transdermal nicotine patch.

Enrollment

54 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Smoking 10 or more cigarettes per day
Regular access to the internet
BMI>=25

Exclusion criteria

Type I diabetes or Type II diabetes requiring medication
Alcohol or drug dependence within the past year
Females with current pregnancy or breastfeeding or intention to become pregnant within the next 12 months
Uncontrolled hypertension
Severe chronic obstructive pulmonary disease
Use of an investigational drug within 30 days or current participation in another clinical trial
Current use of tobacco products other than cigarettes or use of marijuana
Use of nicotine replacement therapy, clonidine, varenicline, bupropion, or nortriptyline within the month prior to enrollment
Use of a medication that might affect weight or appetite
History of allergic reactions to adhesives.